Related Experiment Video

Updated: Nov 3, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.1K

More PARP Inhibitors in Pancreatic Cancer?

    Cancer Discovery
    |June 4, 2021
    PubMed

    Insights

    Maintenance therapy using PARP inhibitors is effective for pancreatic cancer patients with BRCA mutations. Further trials are exploring earlier disease stages and combinations with immunotherapy.

    Area of Science:

    • Oncology
    • Genetics

    Background:

    • Poly (ADP-ribose) polymerase (PARP) inhibitors show efficacy in treating pancreatic cancer, particularly in patients with germline and somatic BRCA mutations.
    • Current research is expanding the application of PARP inhibitors to earlier stages of pancreatic cancer.

    Discussion:

    • Investigating PARP inhibitors in patients with other homologous recombination repair (HRR) deficiencies beyond BRCA mutations.
    • Exploring the synergistic potential of combining PARP inhibitors with immunotherapy to enhance treatment outcomes.

    Key Insights:

    • PARP inhibitors offer a viable maintenance therapy for BRCA-mutated pancreatic cancer.
    • Clinical trials are actively evaluating expanded indications and combination strategies for PARP inhibitors.

    Outlook:

    • Future research will focus on optimizing PARP inhibitor therapy for a broader range of pancreatic cancer patients.
    • Combination therapies, including immunotherapy, hold promise for improving survival rates in pancreatic cancer.

    More Related Videos

    Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

    Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

    Published on: August 21, 2013

    15.2K
    A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation08:05

    A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

    Published on: June 8, 2018

    11.7K

    Related Concept Videos

    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    5.1K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.0K